Литература/References
1. Ketema E.B., Kibret K.T. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health. 2015; 73: 43. DOI: https://doi.org/10.1186/s13690-015-0088-6
2. Home P.D. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab. 2015; 17 (11): 1011–20. DOI: https://doi.org/10.1111/dom.12501
3. Inzucchi S.E. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38 (1): 140–9. DOI: https://doi.org/10.2337/dc14-2441
4. Dovc K., Battelino T. Time in range centered diabetes care. Clin Pediatr Endocrinol. 2021; 30 (1): 1–10. DOI: https://doi.org/10.1297/cpe.30.1
5. Lane W., et al. 56th EASD Annual Meeting of the European Association for the Study of Diabetes. 2020. Sep. PMID: 32840677. PMCID: PMC 7445463. DOI: https://doi.org/10.1007/s00125-020-05221-5
6. Bode В.W., Johnson J.A., Hyveled L., et al. Improved postprandial glycemic control with faster-acting insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Diabetes Technol. Ther. 2017; 19 (1): 25–33. DOI: https://doi.org/10.1089/dia. 2016.0350
7. Heise T., Pieber T.R., Danne T., et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017; 56 (5): 551–9. DOI: https://doi.org/10.1007/s40262-017-0514-8
8. Russell-Jones D., Bode В.W., De Block C., et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017; 40 (7): 943–50. DOI: https://doi.org/10.2337/dc16-1771
9. Senior P., Hramiak I. Fast-acting insulin aspart and the need for new mealtime insulin analogues in adults with type 1 and type 2 diabetes: a Canadian perspective. Can J Diabetes. 2019; 43 (7): 515–23. DOI: https://doi.org/10.1016/j.jcjd.2019.01.004
10. Klonoff D.C., Evans M.L., Lane W., et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019; 21 (4): 961–7. DOI: https://doi.org/10.1111/dom.13610
11. Shiramoto M., Nishida T., Hansen A.K., Haahr H. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. J Diabetes Investig. 2018; 9 (2): 303–10. DOI: https://doi.org/10.1111/jdi.12697
12. Billion L., Charleer S., Verbraeken L., et al. Glucose control using fast-acting insulin aspart in a real-world setting: a 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. Diabetes Obes Metab. 2021; 23 (12): 2716–27. DOI: https://doi.org/10.1111/dom.14527
13. Danne T., Nimri R., Battelino T., et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40 (12): 1631–40. DOI: https://doi.org/10.2337/dc17-1600
14. Battelino T., Danne T., Bergenstal R.M., et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019; 42 (8): 1593–603. DOI: https://doi.org/10.2337/dci19-0028
15. World Medical Association: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310 (20): 2191–4. DOI: https://doi.org/10.1001/jama.2013.281053
16. Guidelines for Good Pharmacoepidemiology Practice (GPP). Pharmacoepidemiol Drug Saf. 2016; 25 (1): 2–10. DOI: https://doi.org/10.1002/pds.3891
17. Bode B.W., Iotova V., Kovarenko M., et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 trial. Diabetes Care. 2019; 42 (7): 1255–62. DOI: https://doi.org/10.2337/dc19-0009
18. Zijlstra E., Demissie M., Graungaard T., et al. Investigation of pump compatibility of fast-acting insulin aspart in subjects with type 1 diabetes. J Diabetes Sci Technol. 2018; 12 (1): 145–151. DOI: https://doi.org/10.1177/1932296817730375
19. Hayek A.A., Robert A.A., Al Dawish M.A. Acceptability of the FreeStyle Libre flash glucose monitoring system: the experience of young patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2020; 13: 1179551420910122. DOI: https://doi.org/10.1177/1179551420910122